The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma Horwitz, S. M., Feldman, T. A., Hess, B. T., Khodadoust, M. S., Kim, Y. H., Munoz, J., Patel, M. R., Phillips, T. J., Smith, S. D., Smith, S. M., Wilcox, R. A., Steele, A., Pandey, A., Birrell, M. R., Leeds, J. M., Conley, P. B., Michelson, G., Coffey, G. P., Curnutte, J. T., Hamlin, P. A. AMER SOC HEMATOLOGY. 2018

View details for DOI 10.1182/blood-2018-99-119944

View details for Web of Science ID 000454837603031